Mark Breidenbach
Stock Analyst at Oppenheimer
(1.61)
# 3,503
Out of 5,140 analysts
52
Total ratings
30.91%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.57 | +345.86% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $18.24 | +64.47% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $12.03 | +689.69% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.78 | +423.01% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.30 | +3,245.60% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $15.06 | +1,493.63% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.83 | +5,553.71% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.18 | +221.10% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.39 | +2,202.16% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.44 | +514.75% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $0.56 | +21,328.57% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.03 | +946,501.94% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.57
Upside: +345.86%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $18.24
Upside: +64.47%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $12.03
Upside: +689.69%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.78
Upside: +423.01%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.30
Upside: +3,245.60%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $15.06
Upside: +1,493.63%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.83
Upside: +5,553.71%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.18
Upside: +221.10%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.39
Upside: +2,202.16%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.44
Upside: +514.75%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $0.56
Upside: +21,328.57%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.03
Upside: +946,501.94%